DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED

Dawnrays Pharmaceutical (Holdings) Limited

2348

KYG2687M1006

Pharmaceuticals

Delayed Hong Kong S.E. Other stock markets 04:08:16 2024-04-24 am EDT			5-day change	1st Jan Change
1.17 ^HKD	-1.68%		0.00%	+11.43%

Mar. 26	Dawnrays Pharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 12 June 2024	CI
Mar. 25	Dawnrays' 2023 Profit Falls 9% on Lower Revenue	MT

Tranche Update on Dawnrays Pharmaceutical Limited's Equity Buyback Plan announced on August 27, 2020.

September 15, 2021 at 04:32 am EDT

From January 1, 2021 to May 28, 2021, the company has repurchased 8,608,000 shares, representing 0.57% for HKD 11.44 million. With this, the company has completed the repurchase of 49,088,000 shares, representing 3.26% for HKD 61.39 million under the buyback announced on August 27, 2020.

Latest news about Dawnrays Pharmaceutical (Holdings) Limited

Dawnrays Pharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 12 June 2024	Mar. 26	CI
Dawnrays' 2023 Profit Falls 9% on Lower Revenue	Mar. 25	MT
Dawnrays Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22	CI
Akeso Unit Buys 35% Stake in Biopharmaceutical Firm from Dawnrays; Akeso Shares Slide 3%	Feb. 08	MT
Dawnrays Pharmaceutical Limited Declares Interim Dividend for the Year Ending December 31, 2023, Payable on October 5, 2023	23-08-25	CI
Dawnrays Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
Dawnrays Pharmaceutical Limited Announces the National Medical Products Administration Accepts the New Drug Application for Ebronucimab Injection	23-06-02	CI
Dawnrays Pharmaceutical Limited Approves Final Dividend for the Year Ended 31 December 2022	23-05-25	CI
Dawnrays Pharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2022, Payable on 13 June 2023	23-03-26	CI
Dawnrays Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-26	CI
Dawnrays Pharmaceutical Unit to Provide $14.4 Million Loan to AD Pharmaceuticals	22-10-25	MT
Dawnrays Pharmaceutical Limited(SEHK:2348) dropped from S&P Global BMI Index	22-09-19	CI
Dawnrays Pharmaceutical Limited Announces Interim Semi-Annual Ordinary Dividend for the Six Months Ended 30 June 2022, Payable on 05 October 2022	22-08-26	CI
Dawnrays Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-26	CI
Dawnrays Pharmaceutical Limited Declares Final Dividend for the Year Ended December 31, 2021	22-05-27	CI
Dawnrays Pharmaceutical Limited Proposes to Declare Final Dividend for the Year Ended December 31, 2021	22-04-21	CI
Dawnrays Pharmaceutical Limited Announces Final Dividend for the Year Ended 31 December 2021, Payable on 15 June 2022	22-03-27	CI
Dawnrays Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-27	CI
Dawnrays Pharma CEO Resigns	22-02-17	MT
Dawnrays Pharmaceutical Limited Announces Resignation of Chen Shaojun as Executive Director, Effective February 16, 2022	22-02-16	CI
Dawnrays Pharmaceutical Limited Announces Executive Changes	22-02-16	CI
Dawnrays Pharma Unit to Sell 35% Stake in Solvent Recovery Services Provider for Nearly $9 Million	22-01-26	MT
Dawnrays Pharmaceutical : Arm Seeks Marketing Nod for Injectable Products in China	21-09-24	MT
Tranche Update on Dawnrays Pharmaceutical Limited's Equity Buyback Plan announced on August 27, 2020.	21-09-15	CI
Dawnrays Pharmaceutical : , Akeso Raise Joint Venture Capital, Start Phase Three Clinical Trial of Therapeutic Antibody	21-09-10	MT

Chart Dawnrays Pharmaceutical (Holdings) Limited

Duration

Period

Chart Dawnrays Pharmaceutical (Holdings) Limited

More charts

Company Profile

Dawnrays Pharmaceutical (Holdings) Limited is an investment holding company principally engaged in the development, manufacture and sale of non-patented pharmaceutical medicines. The products include intermediate pharmaceutical, bulk medicines and finished drugs. The Company operates its business through two segments. The Intermediates and Bulk Medicines segment is engaged in the manufacture and sale of intermediates and bulk medicines. The Finished Drugs segment is engaged in the manufacture and sale of finished drugs, including antibiotics finished drugs and non-antibiotics finished drugs.

Sector

Pharmaceuticals

Calendar

2024-05-27 - Final dividend

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED	+11.43%	224M
ELI LILLY AND COMPANY	+25.61%	660B
NOVO NORDISK A/S	+23.09%	562B
JOHNSON & JOHNSON	-5.24%	358B
MERCK & CO., INC.	+16.49%	322B
ABBVIE INC.	+8.28%	297B
ASTRAZENECA PLC	+12.83%	219B
ROCHE HOLDING AG	-9.86%	196B
NOVARTIS AG	+6.67%	199B
PFIZER, INC.	-8.75%	149B